Abstract
The Oncotype DX Breast Recurrence Score® test identifies patients with HR+/HER2- early breast cancer who are most likely to benefit from adjuvant chemotherapy and reports a Recurrence Score® (RS) result. Based on the RxPONDER study, postmenopausal women with node-positive tumours (N1, 1-3 axillary lymph modes) and RS results 0-25 can be safely spared chemotherapy. An economic evaluation using a decision model was conducted to estimate the cost-effectiveness of the Oncotype DX® test compared to clinical risk alone from a healthcare cost perspective in Ontario, Canada in HR+/HER2- node-positive early breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
